1986-90, McGill University Faculty of Medicine, Canada, B.Sc., Biochemistry
1990-93, University of Montreal, Canada, Other, Biochemistry
1993-98, University of Ottawa, Canada, Ph.D., Biochemistry
1997-01, J. David Gladstone Institutes, Postdoctoral Fellow, Mouse Models of Human Disease
2001-04, J. David Gladstone Institutes, Postdoctoral Fellow, Mouse Models of Human Disease
Raffai RL, Dong LM, Farese RV, Weisgraber KH. Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. Proc Natl Acad Sci U S A. 98: 11587-91, Sep/25/2001.
Raffai RL, Weisgraber KH. Hypomorphic apolipoprotein E mice: a new model of conditional gene repair to examine apolipoprotein E-mediated metabolism. J Biol Chem. 277: 11064-8, Mar/29/2002.
Raffaï RL, Hasty AH, Wang Y, Mettler SE, Sanan DA, Linton MF, Fazio S, Weisgraber KH. Hepatocyte-derived ApoE is more effective than non-hepatocyte-derived ApoE in remnant lipoprotein clearance. J Biol Chem. 278: 11670-5, Mar/28/2003.
Raffai RL, Loeb SM, Weisgraber KH. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol. 25: 436-41, Feb/2005.
Zhang S, Picard MH, Vasile E, Zhu Y, Raffai RL, Weisgraber KH, Krieger M. Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice. Circulation. 111: 3457-64, Jun/28/2005.